High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity.

de Zegher F, Ong K, van Helvoirt M, Mohn A, Woods K, Dunger D

The Journal of clinical endocrinology and metabolism1 Jan 2002Cited by 67 (Europe PMC)

PMID11788639DOI10.1210/jcem.87.1.8293PepBankPUB-11788639

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanRandomized controlled trialSafety outcome
In short SGA children after GH cessation, the slight insulin increase resembled that in untreated children, whose insulin changed from 3.9 to 5.9 mU/1.
In plain wordsIn short children born SGA, the insulin increase after growth hormone cessation resembled the increase in untreated children.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedPost-treatment insulin versus controls
Study
n: not reported in source
Comparator
non-GH-treated children
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 years of GH treatment, measured 3 months after stoppingAs given in this study (human).
Measurements
Fasting insulin
5.2 mU/1
GH-treated children, 3 months post-GH
Fasting insulin
3.9 mU/1
non-GH-treated children, baseline
Fasting insulin
5.9 mU/1
non-GH-treated children, 2 years
Source sentences
Summary
and the slight increase in fasting insulin levels (5.2 mU/1, p = 0.04) was similar to that observed in non-GH treated children over the 2 yr study period (baseline vs. 2 years: 3.9 vs. 5.9 mU/1, n = 4).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863917
02HumanNon-randomized trialEfficacy outcome
In non-GH-deficient short SGA children, mean first-year height gain during high-dose GH was +1.2 SDS.
In plain wordsIn short children born SGA without GH deficiency, height increased by +1.2 SDS during the first year of high-dose growth hormone.
Peptide
HGH (somatotropin)
Outcome
IncreaseFirst-year height gain
Study
n: not reported in source
Outcome group
Linear growth · Musculoskeletal
Studied dose
100 mcg/kg/day · subcutaneous · yr 1As given in this study (human).
Measurements
mean gain in height SDS in year 1
1.2 SDS
all GH-treated children
Source sentences
Summary
In all GH-treated children, gain in height SDS (mean gain yr 1 = +1.2 SDS) was inversely related to baseline peak overnight GH (r = -0.88, n = 10, p = 0.0008), IFG-I (r = -0.74, n = 11, p = 0.009), and fasting insulin levels (r = -0.71, n = 11, p = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863901
03HumanNon-randomized trialSafety outcome
In short SGA children, high-dose GH increased fasting glucose from 3.7 to 4.4 mmol/l at yr 2 (p = 0.005).
In plain wordsIn short children born SGA, fasting glucose increased from baseline during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFasting glucose during treatment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 yearsAs given in this study (human).
Measurements
fasting glucose
3.7 mmol/l
baseline
fasting glucose
4.4 mmol/l
year 2
Source sentences
Summary
GH treatment increased fasting glucose (means: baseline vs. yr 2: 3.7 vs. 4.4 mmol/l, p = 0.005), insulin (3.8 vs. 13.9 mU/l, p = 0.0002), and proinsulin levels (1.7 vs. 4.5 pmol/l, p = 0.004), and decreased insulin sensitivity (26.9 vs. 4.0 per min/mU/1 x 10(4), p = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863905
04HumanNon-randomized trialSafety outcome
In short SGA children, high-dose GH increased fasting insulin from 3.8 to 13.9 mU/l at yr 2 (p = 0.0002).
In plain wordsIn short children born SGA, fasting insulin increased from baseline during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFasting insulin during treatment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 yearsAs given in this study (human).
Measurements
fasting insulin
3.8 mU/l
baseline
fasting insulin
13.9 mU/l
year 2
Source sentences
Summary
GH treatment increased fasting glucose (means: baseline vs. yr 2: 3.7 vs. 4.4 mmol/l, p = 0.005), insulin (3.8 vs. 13.9 mU/l, p = 0.0002), and proinsulin levels (1.7 vs. 4.5 pmol/l, p = 0.004), and decreased insulin sensitivity (26.9 vs. 4.0 per min/mU/1 x 10(4), p = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863906
05HumanNon-randomized trialSafety outcome
In short SGA children, high-dose GH increased proinsulin from 1.7 to 4.5 pmol/l at yr 2 (p = 0.004).
In plain wordsIn short children born SGA, proinsulin increased from baseline during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseProinsulin during treatment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 yearsAs given in this study (human).
Measurements
proinsulin
1.7 pmol/l
baseline
proinsulin
4.5 pmol/l
year 2
Source sentences
Summary
GH treatment increased fasting glucose (means: baseline vs. yr 2: 3.7 vs. 4.4 mmol/l, p = 0.005), insulin (3.8 vs. 13.9 mU/l, p = 0.0002), and proinsulin levels (1.7 vs. 4.5 pmol/l, p = 0.004), and decreased insulin sensitivity (26.9 vs. 4.0 per min/mU/1 x 10(4), p = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863907
06HumanNon-randomized trialSafety outcome
In short SGA children, high-dose GH decreased insulin sensitivity from 26.9 to 4.0 per min/mU/1 x 10(4) (p = 0.002).
In plain wordsIn short children born SGA, insulin sensitivity decreased from baseline during high-dose growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseInsulin sensitivity during treatment
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 yearsAs given in this study (human).
Measurements
insulin sensitivity
26.9 per min/mU/1 x 10(4)
baseline
insulin sensitivity
4 per min/mU/1 x 10(4)
year 2
Source sentences
Summary
GH treatment increased fasting glucose (means: baseline vs. yr 2: 3.7 vs. 4.4 mmol/l, p = 0.005), insulin (3.8 vs. 13.9 mU/l, p = 0.0002), and proinsulin levels (1.7 vs. 4.5 pmol/l, p = 0.004), and decreased insulin sensitivity (26.9 vs. 4.0 per min/mU/1 x 10(4), p = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863908
07HumanNon-randomized trialSafety outcome
In short SGA children, glucose tolerance decreased from 2.62 to 2.18 min(-1) during GH treatment (p = 0.02).
In plain wordsIn short children born SGA, glucose tolerance decreased from baseline during the first year of growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseGlucose tolerance year one
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · yr 1As given in this study (human).
Measurements
glucose tolerance
2.62 min(-1)
baseline
glucose tolerance
2.18 min(-1)
year 1
Source sentences
Summary
Glucose tolerance initially decreased (baseline: 2.62 min(-1); yr 1: 2.18, p = 0.02; yr 2: 2.39, p = 0.12).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863909
08HumanNon-randomized trialSafety outcome
In short SGA children, glucose tolerance at yr 2 was 2.39 versus baseline 2.62 min(-1) (p = 0.12).
In plain wordsIn short children born SGA, glucose tolerance did not differ significantly from baseline after the second year of growth hormone treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeGlucose tolerance year two
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 yearsAs given in this study (human).
Measurements
Glucose tolerance
2.62 min(-1)
baseline
Glucose tolerance
2.39 min(-1)
year 2 of GH
Source sentences
Summary
Glucose tolerance initially decreased (baseline: 2.62 min(-1); yr 1: 2.18, p = 0.02; yr 2: 2.39, p = 0.12).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863910
09HumanNon-randomized trialSafety outcome
In short SGA children, fasting insulin improved to 5.2 mU/1 by 3 months after GH cessation (p = 0.0003 versus yr 2).
In plain wordsIn short children born SGA, fasting insulin decreased after growth hormone cessation compared with the second treatment year.
Peptide
HGH (somatotropin)
Outcome
DecreaseInsulin after cessation
Study
n: not reported in source
Comparator
yr 2 on GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 years of GH treatment, measured 3 months after stoppingAs given in this study (human).
Measurements
Fasting insulin
5.2 mU/1
3 months post-GH
Source sentences
Summary
However, by 3 months post-GH treatment significant improvements were seen in fasting insulin (post-GH: 5.2 mU/1, p = 0.0003 vs. yr 2), proinsulin (1.7 pmol/l, p = 0.002), and insulin sensitivity (17.6 per min/mU/1 x 10(4), p = 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863911
10HumanNon-randomized trialSafety outcome
In short SGA children, proinsulin improved to 1.7 pmol/l by 3 months after GH cessation (p = 0.002).
In plain wordsIn short children born SGA, proinsulin decreased after growth hormone cessation compared with the second treatment year.
Peptide
HGH (somatotropin)
Outcome
DecreaseProinsulin after cessation
Study
n: not reported in source
Comparator
yr 2 on GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 years of GH treatment, measured 3 months after stoppingAs given in this study (human).
Measurements
Proinsulin
1.7 pmol/l
3 months post-GH
Source sentences
Summary
However, by 3 months post-GH treatment significant improvements were seen in fasting insulin (post-GH: 5.2 mU/1, p = 0.0003 vs. yr 2), proinsulin (1.7 pmol/l, p = 0.002), and insulin sensitivity (17.6 per min/mU/1 x 10(4), p = 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863912
11HumanNon-randomized trialSafety outcome
In short SGA children, insulin sensitivity improved to 17.6 per min/mU/1 x 10(4) by 3 months after GH cessation (p = 0.0001).
In plain wordsIn short children born SGA, insulin sensitivity improved after growth hormone cessation compared with the second treatment year.
Peptide
HGH (somatotropin)
Outcome
IncreaseInsulin sensitivity after cessation
Study
n: not reported in source
Comparator
yr 2 on GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 years of GH treatment, measured 3 months after stoppingAs given in this study (human).
Measurements
Insulin sensitivity
17.6 per min/mU/1 x 10(4)
3 months post-GH
Source sentences
Summary
However, by 3 months post-GH treatment significant improvements were seen in fasting insulin (post-GH: 5.2 mU/1, p = 0.0003 vs. yr 2), proinsulin (1.7 pmol/l, p = 0.002), and insulin sensitivity (17.6 per min/mU/1 x 10(4), p = 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863913
12HumanNon-randomized trialSafety outcome
In short SGA children after GH cessation, fasting glucose was described as similar to baseline at 4.1 mmol/l (p = 0.04).
In plain wordsIn short children born SGA after growth hormone cessation, the abstract described fasting glucose as similar to baseline despite p = 0.04.
Peptide
HGH (somatotropin)
Outcome
MixedPost-treatment fasting glucose versus baseline
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 years of GH treatment, measured 3 months after stoppingAs given in this study (human).
Measurements
Fasting glucose
4.1 mmol/l
3 months post-GH
Source sentences
Summary
Post-GH treatment, fasting glucose levels (4.1 mmol/l, p = 0.04) and glucose tolerance (2.49 min(-1), p = 0.4) were similar to baseline,
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863914
13HumanNon-randomized trialSafety outcome
In short SGA children after GH cessation, glucose tolerance was similar to baseline at 2.49 min(-1) (p = 0.4).
In plain wordsIn short children born SGA after growth hormone cessation, glucose tolerance was similar to baseline.
Peptide
HGH (somatotropin)
Outcome
No significant changePost-treatment glucose tolerance versus baseline
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 years of GH treatment, measured 3 months after stoppingAs given in this study (human).
Measurements
Glucose tolerance
2.49 min(-1)
3 months post-GH
Source sentences
Summary
Post-GH treatment, fasting glucose levels (4.1 mmol/l, p = 0.04) and glucose tolerance (2.49 min(-1), p = 0.4) were similar to baseline,
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863915
14HumanNon-randomized trialSafety outcome
In short SGA children after GH cessation, fasting insulin remained slightly increased at 5.2 mU/1 versus baseline (p = 0.04).
In plain wordsIn short children born SGA, fasting insulin remained slightly higher than baseline after growth hormone cessation.
Peptide
HGH (somatotropin)
Outcome
IncreasePost-treatment insulin versus baseline
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
100 mcg/kg/day · subcutaneous · 2 years of GH treatment, measured 3 months after stoppingAs given in this study (human).
Measurements
Fasting insulin
5.2 mU/1
3 months post-GH
Source sentences
Summary
and the slight increase in fasting insulin levels (5.2 mU/1, p = 0.04)
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863916
15HumanObservational studyOther
In GH-treated short SGA children, height gain was inversely related to baseline IFG-I (r = -0.74, p = 0.009).
In plain wordsIn short children born SGA given growth hormone, greater height gain was linked to lower baseline IFG-I.
Peptide
HGH (somatotropin)
Outcome
Not applicableHeight response and baseline IFG-I
Study
n = 11
Outcome group
Linear growth · Musculoskeletal
Studied dose
100 mcg/kg/day · subcutaneous · yr 1As given in this study (human).
Measurements
correlation (r) between year 1 height SDS gain and baseline IGF-I (written IFG-I in the abstract)
−0.74 r
GH-treated children
Source sentences
Summary
In all GH-treated children, gain in height SDS (mean gain yr 1 = +1.2 SDS) was inversely related to baseline peak overnight GH (r = -0.88, n = 10, p = 0.0008), IFG-I (r = -0.74, n = 11, p = 0.009), and fasting insulin levels (r = -0.71, n = 11, p = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863903
16HumanObservational studyOther
In GH-treated short SGA children, height gain was inversely related to baseline fasting insulin (r = -0.71, p = 0.014).
In plain wordsIn short children born SGA given growth hormone, greater height gain was linked to lower baseline fasting insulin.
Peptide
HGH (somatotropin)
Outcome
Not applicableHeight response and fasting insulin
Study
n = 11
Outcome group
Linear growth · Musculoskeletal
Studied dose
100 mcg/kg/day · subcutaneous · yr 1As given in this study (human).
Measurements
correlation (r) between year 1 height SDS gain and baseline fasting insulin
−0.71 r
GH-treated children
Source sentences
Summary
In all GH-treated children, gain in height SDS (mean gain yr 1 = +1.2 SDS) was inversely related to baseline peak overnight GH (r = -0.88, n = 10, p = 0.0008), IFG-I (r = -0.74, n = 11, p = 0.009), and fasting insulin levels (r = -0.71, n = 11, p = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863904
17HumanObservational studyOther
In GH-treated short SGA children, height gain was inversely related to baseline peak overnight GH (r = -0.88, p = 0.0008).
In plain wordsIn short children born SGA given growth hormone, greater height gain was linked to lower baseline overnight growth hormone.
Peptide
HGH (somatotropin)
Outcome
Not applicableHeight response and baseline GH
Study
n = 10
Outcome group
Linear growth · Musculoskeletal
Studied dose
100 mcg/kg/day · subcutaneous · yr 1As given in this study (human).
Measurements
correlation (r) between year 1 height SDS gain and baseline peak overnight GH
−0.88 r
GH-treated children
Source sentences
Summary
In all GH-treated children, gain in height SDS (mean gain yr 1 = +1.2 SDS) was inversely related to baseline peak overnight GH (r = -0.88, n = 10, p = 0.0008), IFG-I (r = -0.74, n = 11, p = 0.009), and fasting insulin levels (r = -0.71, n = 11, p = 0.014).
2 context sentences(design, population, supporting numbers)
Summary · context
13 non-GH deficient short SGA children were randomised to high-dose GH (100 mcg/kg/day) by daily sc injection (n = 9), or no GH treatment (n = 4) for 2 years (2/4 controls subsequently received GH treatment).
Summary · context
Overnight GH profiles were performed at baseline; intravenous glucose tolerance tests were performed at baseline, yearly on GH treatment, and 3 months post-GH treatment.
Report a problemFND-1178863902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.